Managed Care

 

COPD inhalers – hold your breath

MANAGED CARE February 2014. © MediMedia USA
The Formulary Files

COPD inhalers – hold your breath

Krishna R. Patel, PharmD, RPh

With the approval of Breo Ellipta in May 2013 and Anoro Ellipta in December 2013, formulary decision makers are faced with more treatment options for chronic obstructive pulmonary disease (COPD) than ever before. There are now three inhalers that are combination products of a long-acting beta agonist and a glucocorticoid that can potentially help patients with moderate to severe COPD. Research comparing these available therapeutic options is limited, making differentiation difficult. Despite that, let’s take a look at several notable differences among these drugs.

Administration once daily Administration twice daily Black box warning Approved for COPD Approved for asthma Recommended in GOLD guidelines for moderate–severe COPD
Advair
Breo Ellipta
Symbicort
Source: GOLD (Global Initiative for Chronic Obstructive Lung Disease)

Meetings

PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015

Our other journal

P&T Journal for September 2014

Features

Health Care & Law

Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees

Hospitals Struggle With ACA Challenges

Drug–Gene Interactions: Inherent Variability in Drug Maintenance Dose Requirements

Schizophrenia: Overview and Treatment Options

Pipeline Plus

Schizophrenia Therapy Options Increasing

Departments

Medication Errors

Too Many Abandon the “Second Victims” of Medical Errors

Prescription: Washington

New Controversy for 340B: OPA Rebuffs Ruling by Court

New Drugs/Drug News/New Medical Devices

Pharmaceutical Approval Update

Drug Forecast

Loxapine Inhalation Powder (Adasuve)